Shares of several COVID-19 vaccine developers sank fast enough to reflect investor jitters about vaccine policy given RFK’s ...

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

The immediate aftermath of the nomination saw vaccine stock prices drop on account of Kennedy’s well-publicized views on ...

BioNTech SE (BNTX) has released an update. BioNTech SE is entering a new phase of growth, focusing on expanding its oncology ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...

BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy: Mainz, Germany Friday, November 15, 2024, 14:00 Hrs [IST] BioNTech SE and Biotheus (Biothe ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.